Osteoporosis Drug in Once-a-Week FormProvides information on the once-a-week version of the osteoporosis drug Fosamax from the Merck company.Maryann NapoliHealthfacts
a U.S. affiliate of the Swiss-based Novartis AG. It is the only once-yearly bisphosphonate treatment being studied for osteoporosis and is still in the approval process through the Food and Drug Administration.
and a final decision on the marketing authorisation is expected in the coming months. If approved, Sogroya®will be available in some European countries starting in Q4 2023. It received approval from the...
The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis This study evaluated the efficacy and tolerability of risedronate once a week (35 mg and 50 mg) compared with risedronate 5 mg once daily in women with ost......
The TOWER-GO study, a 72-week, multicenter, open-label, randomized controlled trial, was conducted in patients with GIOP to compare the effects of once-weekly teriparatide and once-weekly alendronate 35 mg on BMD.Materials and methodsPatients (N = 180) with GIOP for whom drug treatment was ...
Food and Drug Administration (FDA) in 2015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odan...
Methods: This was a multicenter, double-blinded, randomized, placebo-controlled study. Postmenopausal women with primary osteoporosis received either 20 units of elcatonin (EL group, n = 433) or placebo (P group, n = 436) once a week for 144 weeks (3 years) intramuscular...
The purpose of this study was to estimate the cost-effectiveness of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Methods A patient-level state-transition model was developed to predict the outcome of patients with osteoporosis who have experienced a previous ...
Under a Creative Commonslicense open access Highlights • We compare once-monthly vs once-daily risedronate in Japanese osteoporosis patients. • Regarding BMD, risedronate 75mg/month efficacy is non-inferior to 2.5mg once/day. • Risedronate 75mg once-monthly and 2.5mg once-daily are similar...
effect occurs more commonly when patients are treated with tenofovir as compared with a regimen that does not contain tenofovir.57 As a result, it is recommended that consideration be given to assessing bone mineral density in tenofovir-treated patients with risk factors for osteoporosis or bone ...